Weight Loss & Metabolic Health
What Is the GLP-1 and Fatty Liver?
Last reviewed: May 2026 · Haute MD Editorial Team
GLP-1 medications significantly improve metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and its more severe form MASH (formerly NASH). Semaglutide has shown resolution of liver inflammation in up to 59% of patients, and tirzepatide demonstrates even stronger effects on liver fat reduction.
What MASLD/MASH are
MASLD is fat accumulation in the liver associated with metabolic dysfunction (obesity, insulin resistance). MASH adds inflammation and can progress to fibrosis, cirrhosis, and liver cancer. It affects 30% of US adults and is now the leading cause of liver transplantation.
Evidence for GLP-1s
Phase 2 trials of semaglutide in MASH showed 59% resolution of steatohepatitis vs. 17% with placebo. Tirzepatide trials show even greater reductions in liver fat (up to 70%). Trial data continues to emerge.
Who should consider it
Adults with obesity and confirmed MASLD/MASH — especially those with elevated liver enzymes, imaging evidence of fatty liver, or biopsy-confirmed inflammation.
Frequently Asked Questions
How is fatty liver diagnosed?
Liver ultrasound, FibroScan (elastography), MRI-PDFF, or liver biopsy. Blood tests (ALT, AST, FIB-4 score) provide screening.
Can MASH be reversed?
Yes — with weight loss of 10%+, inflammation often resolves; with 5-10%, steatosis improves significantly.
Are GLP-1s FDA-approved for MASH?
Not yet specifically — but resmetirom (Rezdiffra) is approved, and GLP-1 trials are underway for direct indication.
Should I avoid alcohol with fatty liver?
Yes — alcohol compounds liver injury and should be minimized or eliminated.
Get Help Now
Speak with a Haute MD Internal Medicine physician
Dr. Alexander Golberg
Internal Medicine · New York, NY
View Profile
Dr. Kern Brar
MD
Internal Medicine · Oceanside, CA
View ProfileAre you a Internal Medicine physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · WEIGHT LOSS & METABOLIC HEALTH
What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound) that produces 20%+ weight loss in clinical trials. Learn how it works.
Read GuideGuide · WEIGHT LOSS & METABOLIC HEALTH
What Is the GLP-1 and Cardiovascular Benefit?
GLP-1 medications like semaglutide (Ozempic, Wegovy) have demonstrated significant cardiovascular benefits beyond weight loss. The SELECT trial showed a.
Read Guide